AUM: $698M · Form ADV, 20 May 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: MRNA | Current | Biological Products, (No Diagnostic Substances) | COM | +175.0% | $77M | +$49M | 7.75% | $80.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: KOD | Current | Biological Products, (No Diagnostic Substances) | COM | 533,113 | -526,617 | -49.7% | 0.82% | $65M | +$15M | 6.51% | $6.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BMY | Current | Pharmaceutical Preparations | COM | +2429.0% | $62M | +$59M | 6.23% | $119B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Spdr Series Trust | Current | Fund | ST STR SP BIOT | -0.4% | $47M | -$0.2M | 4.76% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |||||
| Nasdaq: PCVX | Current | Biological Products, (No Diagnostic Substances) | COM | 400,465 | +11,783 | +3.0% | 0.25% | $40M | +$17M | 4.01% | $9.2B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRON | Current | Pharmaceutical Preparations | COM | +1882.1% | $39M | +$37M | 3.88% | $3.5B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: ABVX | Current | Pharmaceutical Preparations | SPONSORED ADS | 285,909 | -42,726 | -13.0% | $38M | -$84M | 3.86% | $7.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PRAX | Current | Pharmaceutical Preparations | COM NEW | 6,942 | -65,900 | -90.5% | 0.02% | $31M | -$0.3M | 3.13% | $8.7B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ACAD | Current | Pharmaceutical Preparations | COM | 112,000 | +83,901 | +298.6% | 0.06% | $26M | +$26M | 2.66% | $3.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLDX | Current | In Vitro & In Vivo Diagnostic Substances | COM NEW | 518,500 | +40,000 | +8.4% | 0.66% | $25M | +$3M | 2.51% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Newamsterdam Pharma Company | Current | ORDINARY SHARES | +43.5% | $19M | +$6M | 1.96% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||||
| NYSE: RCUS | Current | Pharmaceutical Preparations | COM | 734,559 | +230,000 | +45.6% | 0.51% | $19M | +$3M | 1.91% | $2.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: INCY | Current | Services-Commercial Physical & Biological Research | COM | New | $18M | +$18M | 1.83% | $23.6B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: AMLX | Current | Pharmaceutical Preparations | COM | 561,459 | +443,959 | +377.8% | 0.44% | $16M | +$14M | 1.64% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Rapport Therapeutics, Inc. | Nasdaq: RAPP | Current | Pharmaceutical Preparations | COM | New | $16M | +$16M | 1.63% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |||
| Nasdaq: PHVS | Current | Pharmaceutical Preparations | COM | 502,372 | +193,516 | +62.7% | $16M | +$5M | 1.60% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: KYMR | Current | Biological Products, (No Diagnostic Substances) | COM | +157.5% | $15M | +$9M | 1.50% | $10.2B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Vera Therapeutics, Inc. | Nasdaq: VERA | Current | Pharmaceutical Preparations | CL A | 400,000 | +90,000 | +29.0% | 0.55% | $15M | -$2M | 1.46% | $1.9B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SEPN | Current | Pharmaceutical Preparations | COM | 100,047 | +100,047 | New | 0.21% | $13M | +$13M | 1.27% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: ANRO | Current | Pharmaceutical Preparations | COM SHS | 482,338 | +75,000 | +18.4% | 1.20% | $12M | +$2M | 1.24% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Cybin Inc | Current | COM NEW | 487,575 | +355,422 | +268.9% | $12M | +$11M | 1.22% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: CTNM | Current | Pharmaceutical Preparations | CL A | 594,666 | -213,208 | -26.4% | $12M | -$1M | 1.21% | $355M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: COGT | Current | Pharmaceutical Preparations | COM | 370,084 | 0 | 0.0% | 0.21% | $12M | -$2M | 1.19% | $4.8B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORIC | Current | Pharmaceutical Preparations | COM | 522,765 | +522,765 | New | 0.50% | $11M | +$11M | 1.11% | $800M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SMMT | Current | Pharmaceutical Preparations | COM | New | $11M | +$11M | 1.11% | $8.5B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: ANIP | Current | Pharmaceutical Preparations | COM | 149,065 | -123,020 | -45.2% | $11M | -$12M | 1.09% | $1.6B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ELVN | Current | Pharmaceutical Preparations | COM | 232,055 | +105,514 | +83.4% | 0.32% | $11M | +$4M | 1.07% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MAZE | Current | Biological Products, (No Diagnostic Substances) | COM | 301,402 | -77,597 | -20.5% | 0.55% | $8M | -$3M | 0.82% | $1.8B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CCCC | Current | Biological Products, (No Diagnostic Substances) | COM STK | 1,933,000 | -500,000 | -20.6% | 1.47% | $8M | -$3M | 0.81% | $320M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Uniqure NV | Current | SHS | 49,800 | +233.7% | $8M | +$5M | 0.77% | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |||||
| Surrozen, Inc./DE | Nasdaq: SRZN | Current | Biological Products, (No Diagnostic Substances) | COM NEW | New | $8M | +$8M | 0.76% | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Cue Biopharma, Inc. | Nasdaq: CUE | Current | Pharmaceutical Preparations | COM | 290,633 | +186,269 | +178.5% | 3.48% | $8M | +$4M | 0.76% | $2M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| EUPRAXIA PHARMACEUTICALS INC. | Nasdaq: EPRX | Current | Pharmaceutical Preparations | COM | 809,741 | 0 | 0.0% | $7M | +$2M | 0.74% | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ERAS | Current | Pharmaceutical Preparations | COM | New | $7M | +$7M | 0.74% | $5.0B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Tectonic Therapeutic, Inc. | Nasdaq: TECX | Current | Biological Products, (No Diagnostic Substances) | COM | 306,338 | +100,501 | +48.8% | 1.54% | $7M | +$0.1M | 0.72% | $411M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: MNPR | Current | Pharmaceutical Preparations | COM NEW | 86,761 | +38,900 | +81.3% | 1.28% | $7M | +$2M | 0.70% | $476M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CBIO | Current | Pharmaceutical Preparations | COM | 150,061 | +150,061 | New | 0.39% | $7M | +$7M | 0.66% | $539M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Alpha Cognition Inc. | Nasdaq: ACOG | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 701,259 | -135,000 | -16.1% | 3.18% | $6M | +$0.3M | 0.63% | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMNM | Current | Pharmaceutical Preparations | COM | 285,000 | +225,000 | +375.0% | 0.24% | $6M | +$5M | 0.62% | $2.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: JBIO | Current | Pharmaceutical Preparations | COM NEW | 427,349 | 0 | 0.0% | 0.62% | $6M | -$3M | 0.60% | $1.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Faeth Therapeutics, Inc. | Nasdaq: FTH | Current | Pharmaceutical Preparations | COM NEW | 199,694 | +164,308 | +464.3% | 0.77% | $6M | +$5M | 0.60% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FRNM | Current | Services-Medical Laboratories | COMMON STOCK | 362,626 | +362,626 | New | 0.33% | $6M | +$6M | 0.57% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Proqr Thrapeutics N V | Current | SHS EURO | 3,425,930 | 0 | 0.0% | $6M | -$0.7M | 0.57% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Cardiol Therapeutics Inc. | Nasdaq: CRDL | Current | Biological Products, (No Diagnostic Substances) | COM CL A | 3,325,000 | 0 | 0.0% | $6M | +$2M | 0.56% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: OLMA | Current | Pharmaceutical Preparations | COM | 383,281 | 0 | 0.0% | 0.44% | $5M | -$2M | 0.55% | $626M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| RELMADA THERAPEUTICS, INC. | Nasdaq: RLMD | Current | Pharmaceutical Preparations | COM | 1,448,359 | -700,000 | -32.6% | 1.36% | $5M | -$9M | 0.55% | $332M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Pelthos Therapeutics Inc. | NYSE: PTHS | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 256,598 | 0 | 0.0% | 6.53% | $5M | -$2M | 0.54% | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Inventiva S.A. | Nasdaq: IVA | Current | Pharmaceutical Preparations | ADS | 1,129,101 | 0 | 0.0% | $5M | +$1M | 0.54% | $825M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Ovid Therapeutics Inc. | Nasdaq: OVID | Current | Pharmaceutical Preparations | COM | 2,119,704 | -150,000 | -6.6% | 1.12% | $5M | -$0.8M | 0.53% | $442M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| SPRUCE BIOSCIENCES, INC. | Nasdaq: SPRB | Current | Pharmaceutical Preparations | COM NEW | 101,356 | -20,000 | -16.5% | 3.53% | $5M | -$2M | 0.50% | $116M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DYN | Current | Pharmaceutical Preparations | COM | New | $5M | +$5M | 0.49% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Vor Biopharma Inc. | Nasdaq: VOR | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 250,000 | +250,000 | New | 0.41% | $5M | +$5M | 0.48% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Vogenx, Inc. | Nasdaq: VOGX | Current | Pharmaceutical Preparations | COM | 208,836 | +208,836 | New | 1.41% | $5M | +$5M | 0.48% | $190M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Viridian Therapeutics, Inc.\DE | Nasdaq: VRDN | Current | Pharmaceutical Preparations | COM | 225,000 | -200,000 | -47.1% | 0.20% | $5M | -$3M | 0.47% | $3.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DRUG | Current | Pharmaceutical Preparations | COM NEW | 88,951 | 0 | 0.0% | $4M | -$2M | 0.45% | $204M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: SLS | Current | Pharmaceutical Preparations | COM NEW | -16.6% | $4M | -$0.9M | 0.44% | $3.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Zura Bio Ltd | Nasdaq: ZURA | Current | Biological Products, (No Diagnostic Substances) | CLASS A ORD SHS | 1,018,492 | -200,000 | -16.4% | 1.06% | $4M | -$3M | 0.43% | $92M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: XNCR | Current | Pharmaceutical Preparations | COM | New | $4M | +$4M | 0.43% | $2.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| CUMBERLAND PHARMACEUTICALS INC | Nasdaq: CPIX | Current | Pharmaceutical Preparations | COM | 503,153 | 0 | 0.0% | 3.36% | $4M | +$0.7M | 0.40% | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Rezolute, Inc. | Nasdaq: RZLT | Current | Pharmaceutical Preparations | COM NEW | 935,012 | 0 | 0.0% | 0.97% | $4M | -$1.0M | 0.39% | $499M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Amanat Acquisition Corp | Current | CL A ORD | 349,836 | +199,836 | +133.2% | $4M | +$2M | 0.37% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: BCAX | Current | Pharmaceutical Preparations | COM | New | $4M | +$4M | 0.37% | $605M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Camp4 Therapeutics Corp | Nasdaq: CAMP | Current | Pharmaceutical Preparations | COM | 912,906 | +912,906 | New | 1.45% | $4M | +$4M | 0.37% | $251M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: OCGN | Current | Biological Products, (No Diagnostic Substances) | COM | 3,562,972 | -400,000 | -10.1% | 1.05% | $4M | -$2M | 0.37% | $249M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALEC | Current | Biological Products, (No Diagnostic Substances) | COM | 1,982,606 | 0 | 0.0% | 1.33% | $4M | -$0.3M | 0.37% | $342M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AVTX | Current | Pharmaceutical Preparations | COM NEW | 90,183 | 0 | 0.0% | 0.16% | $4M | +$2M | 0.36% | $390M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Silence Therapeutics plc | Nasdaq: SLN | Current | Pharmaceutical Preparations | ADS | 821,790 | -8,994 | -1.1% | 0.44% | $3M | +$1M | 0.33% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| NYSE: DNA | Current | Biological Products, (No Diagnostic Substances) | CL A NEW | 250,000 | +250,000 | New | $3M | +$3M | 0.32% | $532M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Atea Pharmaceuticals, Inc. | Nasdaq: AVIR | Current | Pharmaceutical Preparations | COM | New | $3M | +$3M | 0.32% | $316M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |||
| IRulya Therapeutics Inc. | Nasdaq: IRLA | Current | Biological Products, (No Diagnostic Substances) | COM | 95,652 | +23,401 | +32.4% | 0.88% | $3M | +$2M | 0.30% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALMS | Current | Pharmaceutical Preparations | COM | 41,177 | -829,371 | -95.3% | $3M | -$32M | 0.30% | $562M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Q32 Bio Inc. | Nasdaq: QTTB | Current | Pharmaceutical Preparations | COM | 345,000 | -85,000 | -19.8% | 1.15% | $3M | -$5M | 0.29% | $254M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ARVN | Current | Pharmaceutical Preparations | COM | 358,257 | 0 | 0.0% | 0.55% | $3M | -$0.2M | 0.28% | $441M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Connect Biopharma Hldgs Ltd | Current | SHS | 2,235,534 | -2,303,000 | -50.7% | $2M | -$8M | 0.25% | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Rein Therapeutics, Inc. | Nasdaq: RNTX | Current | Pharmaceutical Preparations | COM NEW | 2,950,000 | 0 | 0.0% | 3.42% | $2M | -$0.7M | 0.24% | $32M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| KAZIA THERAPEUTICS LTD | Nasdaq: KZIA | Current | Pharmaceutical Preparations | SPONSORED ADS | 246,201 | -150,000 | -37.9% | <0.01% | $2M | -$3M | 0.24% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Acumen Pharmaceuticals, Inc. | Nasdaq: ABOS | Current | Biological Products, (No Diagnostic Substances) | COM | 1,053,797 | 0 | 0.0% | 1.46% | $2M | -$0.5M | 0.24% | $14M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IVVD | Current | Biological Products, (No Diagnostic Substances) | COM | 2,656,570 | 0 | 0.0% | 0.90% | $2M | -$0.0M | 0.23% | $132M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| ProMIS Neurosciences Inc. | Nasdaq: PMN | Current | Pharmaceutical Preparations | COM SHS | 205,000 | 0 | 0.0% | 2.28% | $2M | -$0.5M | 0.22% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Obsidian Therapeutics, Inc. | Nasdaq: OBX | Current | Pharmaceutical Preparations | COM | 158,942 | +158,942 | New | 0.26% | $2M | +$2M | 0.22% | $751M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | COM NEW | 229,215 | -375,000 | -62.1% | 0.39% | $2M | -$21M | 0.22% | $438M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: DCTH | Current | Surgical & Medical Instruments & Apparatus | COM NEW | 135,667 | -50,000 | -26.9% | 0.39% | $2M | -$0.2M | 0.22% | $669M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FDMT | Current | Biological Products, (No Diagnostic Substances) | COM | 150,037 | +150,037 | New | $2M | +$2M | 0.22% | $604M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: STIM | Current | Surgical & Medical Instruments & Apparatus | COM | 810,182 | +109,000 | +15.5% | 1.04% | $2M | +$1.0M | 0.19% | $120M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BHVN | Current | Pharmaceutical Preparations | COM | 133,181 | -615,000 | -82.2% | 0.09% | $2M | -$9M | 0.18% | $2.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Lexeo Therapeutics, Inc. | Nasdaq: LXEO | Current | Biological Products, (No Diagnostic Substances) | COM | 513,011 | 0 | 0.0% | 0.62% | $2M | -$0.7M | 0.17% | $244M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: VSTM | Current | Pharmaceutical Preparations | COM NEW | 213,865 | 0 | 0.0% | 0.17% | $2M | +$0.9M | 0.17% | $864M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Journey Medical Corp | Nasdaq: DERM | Current | Pharmaceutical Preparations | COM | 251,436 | 0 | 0.0% | $2M | -$0.1M | 0.17% | $100M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| IMMUNIC, INC. | Nasdaq: IMUX | Current | Pharmaceutical Preparations | COM NEW | 182,464 | +115,000 | +170.5% | 1.15% | $2M | +$0.7M | 0.17% | $117M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: PEPG | Current | Pharmaceutical Preparations | COM | 693,539 | +246,374 | +55.1% | 1.00% | $2M | +$0.9M | 0.17% | $370M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FULC | Current | Pharmaceutical Preparations | COM | 449,161 | -600,000 | -57.2% | 0.59% | $2M | -$2M | 0.17% | $283M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TYRA | Current | Pharmaceutical Preparations | COM | 65,000 | +65,000 | New | 0.09% | $1M | +$1M | 0.14% | $1.4B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| EyePoint, Inc. | Nasdaq: EYPT | Current | Laboratory Analytical Instruments | COM NEW | 205,056 | -86.9% | 0.18% | $1M | -$9M | 0.14% | $30M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Cabaletta Bio, Inc. | Nasdaq: CABA | Current | Biological Products, (No Diagnostic Substances) | COM | 700,000 | 0 | 0.0% | 0.32% | $1M | -$0.8M | 0.14% | $218M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: TARS | Current | Biological Products, (No Diagnostic Substances) | COM | 16,858 | -14,308 | -45.9% | 0.03% | $1M | -$0.6M | 0.13% | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SION | Current | Pharmaceutical Preparations | COM | 85,300 | -75.5% | 0.19% | $1M | -$4M | 0.12% | $134M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| PALATIN TECHNOLOGIES INC | Nasdaq: PTN | Current | Pharmaceutical Preparations | COM NEW | 130,000 | +130,000 | New | 7.30% | $1M | +$1M | 0.12% | $9M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| iBio, Inc. | Nasdaq: IBIO | Current | Pharmaceutical Preparations | COM NEW | 957,062 | 0 | 0.0% | 1.49% | $1M | -$0.5M | 0.11% | $56M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Lipocine Inc. | Nasdaq: LPCN | Current | Pharmaceutical Preparations | COM NEW | 508,556 | 0 | 0.0% | 4.59% | $1M | -$0.2M | 0.11% | $17M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Spdr S&p 500 Etf TR | NYSE: SPY | Exited | Fund | TR UNIT | 0 | -25,000 | -100.0% | -$193M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Terns Pharmaceuticals Inc | Exited | COM | 0 | -1,456,378 | -100.0% | -$140M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Cidara Therapeutics, Inc. | Exited | COM NEW | 0 | -273,243 | -100.0% | -$127M | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| VERTEX PHARMACEUTICALS INC / MA | Nasdaq: VRTX | Exited | Pharmaceutical Preparations | COM | -100.0% | -$93M | $132B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||||
| UNITED THERAPEUTICS Corp | Nasdaq: UTHR | Exited | Pharmaceutical Preparations | COM | -100.0% | -$89M | $23.8B | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||||
| Nasdaq: CYTK | Exited | Pharmaceutical Preparations | COM NEW | 0 | -283,572 | -100.0% | -$82M | $7.2B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: AMGN | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -45,000 | -100.0% | -$80M | $237B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Invesco QQQ TR | Exited | Fund | UNIT SER 1 | -100.0% | -$58M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||||||
| Nasdaq: IONS | Exited | Pharmaceutical Preparations | COM | -100.0% | -$56M | $4.5B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q2 2026 | 13F, Q2 2026 | ||||||
| GENMAB A/S | Nasdaq: GMAB | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -175,000 | -100.0% | -$53M | $31.7B | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Ishares TR | Exited | Fund | RUSSELL 2000 ETF | -100.0% | -$50M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | |||||||
| NYSE: TSN | Exited | Poultry Slaughtering and Processing | CL A | -100.0% | -$36M | $22.0B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| RAPT Therapeutics | Exited | COM NEW | 0 | -665,271 | -100.0% | -$32M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| OMEROS CORP | Nasdaq: OMER | Exited | Pharmaceutical Preparations | COM | -100.0% | -$26M | $1.0B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||||
| Nasdaq: RVMD | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -163,142 | -100.0% | -$25M | $34.5B | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: SRRK | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$24M | $6.1B | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: CORT | Exited | Pharmaceutical Preparations | COM | 0 | -185,593 | -100.0% | -$20M | $7.1B | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ALNY | Exited | Pharmaceutical Preparations | COM | 0 | -56,594 | -100.0% | -$18M | $19.8B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Crinetics Pharmaceuticals Inc | Exited | COM | -100.0% | -$17M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||||
| Nasdaq: NBIX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -54,062 | -100.0% | -$15M | $15.8B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: NVO | Exited | Pharmaceutical Preparations | ADR | -100.0% | -$15M | $171B | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Karyopharm Therapeutics Inc | KPTIQ | Exited | COM NEW | 0 | -733,435 | -100.0% | -$14M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | |||||
| Verona Pharma PLC | Exited | SPONSORED ADS | 0 | -146,831 | -100.0% | -$14M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Apogee Therapeutics Inc | Exited | COM | 0 | -232,047 | -100.0% | -$14M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| PILGRIMS PRIDE CORP | Nasdaq: PPC | Exited | Poultry Slaughtering and Processing | COM | -100.0% | -$14M | $6.6B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||||
| Dianthus Therapeutics, Inc. /DE/ | Nasdaq: DNTH | Exited | Pharmaceutical Preparations | COM | 0 | -346,001 | -100.0% | -$14M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: CTMX | Exited | Pharmaceutical Preparations | COM | 0 | -3,172,616 | -100.0% | -$14M | $447M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: CRBP | Exited | Pharmaceutical Preparations | COM NEW | 0 | -284,715 | -100.0% | -$13M | $50M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: ORKA | Exited | Pharmaceutical Preparations | COM | 0 | -242,021 | -100.0% | -$12M | Q2 2026 | 14 Aug 2026 | Q1 2025 | Q1 2026 | 13F, Q1 2026 | |||||
| Akero Therapeutics Inc | Exited | COM | 0 | -206,854 | -100.0% | -$12M | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Soleno Therapeutics Inc | Exited | COM | 0 | -344,123 | -100.0% | -$12M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: ANAB | Exited | Pharmaceutical Preparations | COM | 0 | -48,410 | -100.0% | -$11M | $1.4B | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: ARWR | Exited | Pharmaceutical Preparations | COM | 0 | -38,278 | -100.0% | -$11M | $6.2B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: MLTX | Exited | Pharmaceutical Preparations | CLASS A ORD | 0 | -435,839 | -100.0% | -$11M | $939M | Q4 2025 | 18 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: CELC | Exited | Services-Medical Laboratories | COM | 0 | -105,545 | -100.0% | -$11M | $2.8B | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Blueprint Medicines Corp | Exited | COM | 0 | -113,904 | -100.0% | -$10M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Apellis Pharmaceuticals Inc | Exited | COM | 0 | -71,747 | -100.0% | -$10M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: PTGX | Exited | Pharmaceutical Preparations | COM | -100.0% | -$10M | $8.1B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: DXCM | Exited | Surgical & Medical Instruments & Apparatus | COM | -100.0% | -$9M | $29.9B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: PTCT | Exited | Pharmaceutical Preparations | COM | 0 | -118,657 | -100.0% | -$9M | $4.9B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Metsera Inc | Exited | COM | -100.0% | -$9M | Q4 2025 | 18 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||||||
| TRUPANION, INC. | Nasdaq: TRUP | Exited | Hospital & Medical Service Plans | COM | -100.0% | -$9M | $1.6B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | |||||
| Avidity Biosciences Inc | Exited | COM | -100.0% | -$9M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||||||
| Nasdaq: DMRA | Exited | Pharmaceutical Preparations | COM NEW | 0 | -335,710 | -100.0% | -$9M | $1.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Ventyx Biosciences Inc | Exited | COM | 0 | -958,704 | -100.0% | -$9M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: AXSM | Exited | Pharmaceutical Preparations | COM | -100.0% | -$8M | $7.1B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: CGON | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -199,473 | -100.0% | -$8M | $7.3B | Q1 2026 | 15 May 2026 | Q2 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| PALVELLA THERAPEUTICS, INC. | Nasdaq: PVLA | Exited | Pharmaceutical Preparations | COM | 0 | -64,626 | -100.0% | -$8M | $2.1B | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | |||
| MBX Biosciences, Inc. | Nasdaq: MBX | Exited | Pharmaceutical Preparations | COM | 0 | -48,071 | -100.0% | -$8M | $2.7B | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: CALM | Exited | Agricultural Prod-Livestock & Animal Specialties | COM NEW | -100.0% | -$8M | $3.3B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Arcellx | Exited | COMMON STOCK | -100.0% | -$7M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||||
| Nasdaq: MLYS | Exited | Pharmaceutical Preparations | COM | 0 | -200,000 | -100.0% | -$7M | $1.3B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Black Diamond Therapeutics, Inc. | Nasdaq: BDTX | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$7M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: AGIO | Exited | Pharmaceutical Preparations | COM | 0 | -115,489 | -100.0% | -$7M | $1.7B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: IMVT | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$7M | $6.7B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Exited | Pharmaceutical Preparations | COM NEW | 0 | -282,159 | -100.0% | -$7M | $9.3B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Hims & Hers Health, Inc. | NYSE: HIMS | Exited | Services-Offices & Clinics of Doctors of Medicine | COM CL A | 0 | -188,381 | -100.0% | -$7M | $3.8B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | |||
| Nasdaq: EWTX | Exited | Pharmaceutical Preparations | COM | 0 | -280,000 | -100.0% | -$6M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||||
| Eli Lilly | NYSE: LLY | Exited | Pharmaceutical Preparations | COM | 0 | -6,547 | -100.0% | -$6M | $1.20T | Q2 2026 | 14 Aug 2026 | Q1 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: NRIX | Exited | Pharmaceutical Preparations | COM | 0 | -260,000 | -100.0% | -$6M | $1.5B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: SPRY | Exited | Pharmaceutical Preparations | COM | -100.0% | -$6M | $338M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: ONC | Exited | Pharmaceutical Preparations | SPONSORED ADR | -100.0% | -$6M | $45.7B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Syndax Pharmaceuticals Inc | Nasdaq: SNDX | Exited | Pharmaceutical Preparations | COM | 0 | -333,733 | -100.0% | -$5M | $822M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: MDGL | Exited | Pharmaceutical Preparations | COM | -100.0% | -$5M | $9.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: BIOA | Exited | Pharmaceutical Preparations | COM | 0 | -200,000 | -100.0% | -$5M | $216M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: GPCR | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -163,237 | -100.0% | -$5M | $1.2B | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Liquidia Corp | Nasdaq: LQDA | Exited | Pharmaceutical Preparations | COM NEW | -100.0% | -$5M | $5.1B | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||||
| Nasdaq: ARCT | Exited | Pharmaceutical Preparations | COM | 0 | -10,721 | -100.0% | -$4M | $219M | Q4 2025 | 18 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: LENZ | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -149,502 | -100.0% | -$4M | $105M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: ARGX | Exited | Biological Products, (No Diagnostic Substances) | SPONSORED ADR | 0 | -5,942 | -100.0% | -$4M | $59.2B | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: ADMA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -234,854 | -100.0% | -$4M | $3.0B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: BBIO | Exited | Pharmaceutical Preparations | COM | 0 | -57,417 | -100.0% | -$4M | $15.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: LEGN | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -226,888 | -100.0% | -$4M | $3.1B | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: ABSI | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -353,772 | -100.0% | -$4M | $1.4B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Teva Pharmaceutical Inds Ltd | Exited | SPONSORED ADS | -100.0% | -$4M | Q4 2025 | 18 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||||||
| Nasdaq: CLYM | Exited | Pharmaceutical Preparations | COM | 0 | -300,000 | -100.0% | -$4M | $545M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: ALT | Exited | Pharmaceutical Preparations | COM NEW | -100.0% | -$4M | $274M | Q4 2025 | 18 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: KRYS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -14,814 | -100.0% | -$4M | $9.4B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Trevi Therapeutics, Inc. | Nasdaq: TRVI | Exited | Pharmaceutical Preparations | COM | 0 | -575,000 | -100.0% | -$4M | $2.0B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: PRME | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -150,000 | -100.0% | -$4M | $856M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: TGTX | Exited | Pharmaceutical Preparations | COM | 0 | -117,903 | -100.0% | -$4M | $9.8B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ZBIO | Exited | Pharmaceutical Preparations | COM | -100.0% | -$3M | $1.7B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: AQST | Exited | Pharmaceutical Preparations | COM | -100.0% | -$3M | $466M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Gossamer Bio Inc | Exited | COM | -100.0% | -$3M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||||
| GALECTIN THERAPEUTICS INC | Nasdaq: GALT | Exited | Pharmaceutical Preparations | COM NEW | 0 | -100 | -100.0% | -$3M | $283M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Forte Biosciences Inc. | Exited | COM NEW | 0 | -118,972 | -100.0% | -$3M | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: NKTR | Exited | Pharmaceutical Preparations | COM NEW | -100.0% | -$3M | $1.1B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Upstream Bio, Inc. | Nasdaq: UPB | Exited | Pharmaceutical Preparations | COM | 0 | -161,113 | -100.0% | -$3M | $110M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | |||
| CervoMed Inc. | Nasdaq: CRVO | Exited | Pharmaceutical Preparations | COM | 0 | -202,345 | -100.0% | -$3M | $20M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Keros Therapeutics, Inc. | Nasdaq: KROS | Exited | Pharmaceutical Preparations | COM | 0 | -274,009 | -100.0% | -$3M | $224M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | |||
| Eledon Pharmaceuticals, Inc. | Nasdaq: ELDN | Exited | Pharmaceutical Preparations | COM | 0 | -1,000,221 | -100.0% | -$3M | $160M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: BIIB | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -21,516 | -100.0% | -$3M | $36.5B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Perceptive Cap Solutions Cor | Exited | CL A ORD SHS | 0 | -240,951 | -100.0% | -$3M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: SRPT | Exited | Pharmaceutical Preparations | COM | -100.0% | -$3M | $1.5B | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: VIR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -293,258 | -100.0% | -$3M | $1.7B | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Aligos Therapeutics, Inc. | Nasdaq: ALGS | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -64,300 | -100.0% | -$3M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| ABEONA THERAPEUTICS INC. | Nasdaq: ABEO | Exited | Pharmaceutical Preparations | COM NEW | 0 | -533,581 | -100.0% | -$3M | $151M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| NextCure, Inc. | Nasdaq: NXTC | Exited | Pharmaceutical Preparations | COM NEW | 0 | -238,303 | -100.0% | -$3M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: SANA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -365,000 | -100.0% | -$2M | $521M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: ANNX | Exited | Pharmaceutical Preparations | COM | 0 | -430,244 | -100.0% | -$2M | $651M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| ZEVRA THERAPEUTICS, INC. | Nasdaq: ZVRA | Exited | Pharmaceutical Preparations | COM NEW | 0 | -292,772 | -100.0% | -$2M | $540M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: RLAY | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -467,362 | -100.0% | -$2M | $3.5B | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: XENE | Exited | Pharmaceutical Preparations | COM | 0 | -62,052 | -100.0% | -$2M | $3.7B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: BBOT | Exited | Pharmaceutical Preparations | COM NEW | 0 | -270,231 | -100.0% | -$2M | $149M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nuvalent Inc | Exited | COM | 0 | -23,594 | -100.0% | -$2M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: NVAX | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | -100.0% | -$2M | $1.3B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: JAZZ | Exited | Pharmaceutical Preparations | SHS USD | 0 | -12,460 | -100.0% | -$2M | $15.2B | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: EOLS | Exited | Pharmaceutical Preparations | COM | 0 | -193,265 | -100.0% | -$2M | $463M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: REPL | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$2M | $1.8B | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: GERN | Exited | Pharmaceutical Preparations | COM | 0 | -1,600,000 | -100.0% | -$2M | $588M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Acelyrin Inc | Exited | COM | 0 | -676,608 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Cardiff Oncology, Inc. | Nasdaq: CRDF | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -450,000 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: TARA | Exited | Biological Products, (No Diagnostic Substances) | COM STK | 0 | -350,489 | -100.0% | -$2M | $148M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: LRMR | Exited | Pharmaceutical Preparations | COM | -100.0% | -$2M | $337M | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Reneo Pharmaceuticals Inc | Exited | COM | 0 | -1,025,668 | -100.0% | -$2M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Biomea Fusion, Inc. | Nasdaq: BMEA | Exited | Pharmaceutical Preparations | COM | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Achilles Therapeutics PLC | Exited | SPONSORED ADS | 0 | -1,441,141 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Verve Therapeutics Inc | Exited | COM | 0 | -358,393 | -100.0% | -$2M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: RCKT | Exited | Pharmaceutical Preparations | COM | 0 | -221,911 | -100.0% | -$1M | $236M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: WVE | Exited | Pharmaceutical Preparations | SHS | 0 | -85,285 | -100.0% | -$1M | $536M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: TVTX | Exited | Pharmaceutical Preparations | COM | -100.0% | -$1M | $4.6B | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Catalyst Pharmaceuticals Inc | Exited | COM | 0 | -57,388 | -100.0% | -$1M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: JANX | Exited | Pharmaceutical Preparations | COM | 0 | -54,691 | -100.0% | -$1M | $630M | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: ZYME | Exited | Pharmaceutical Preparations | COM | 0 | -72,787 | -100.0% | -$1M | $1.9B | Q4 2025 | 18 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Marinus Pharmaceuticals Inc | Exited | COM NEW | 0 | -706,154 | -100.0% | -$1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: CRVS | Exited | Pharmaceutical Preparations | COM | -100.0% | -$1M | $844M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Elicio Therapeutics, Inc. | Nasdaq: ELTX | Exited | Pharmaceutical Preparations | COM | 0 | -100,000 | -100.0% | -$1M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: NUVB | Exited | Pharmaceutical Preparations | COM CL A | 0 | -619,258 | -100.0% | -$1M | $1.3B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: TDOC | Exited | Services-Offices & Clinics of Doctors of Medicine | COM | 0 | -150,000 | -100.0% | -$1M | $1.4B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Allakos Inc | Exited | COM | 0 | -971,950 | -100.0% | -$1M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: ROIV | Exited | Pharmaceutical Preparations | SHS | 0 | -100,609 | -100.0% | -$1M | $28.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: DFTX | Exited | Medicinal Chemicals & Botanical Products | COM SHS | 0 | -58,803 | -100.0% | -$1M | $4.0B | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||
| Milestone Pharmaceuticals Inc. | Nasdaq: MIST | Exited | Pharmaceutical Preparations | COM | 0 | -466,030 | -100.0% | -$1M | $50M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| OnKure Therapeutics, Inc. | Nasdaq: OKUR | Exited | Pharmaceutical Preparations | COM CL A | 0 | -253,754 | -100.0% | -$1M | $114M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Tourmaline Bio Inc | Exited | COM | 0 | -67,927 | -100.0% | -$1M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: SGMT | Exited | Pharmaceutical Preparations | COM SER A | 0 | -387,565 | -100.0% | -$1M | $692M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Perspective Therapeutics, Inc. | NYSE: CATX | Exited | Pharmaceutical Preparations | COM NEW | -100.0% | -$1M | $95M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||||
| Third Harmonic Bio Inc | Exited | COM | 0 | -100,000 | -100.0% | -$1M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Inflarx NV | Exited | COM | 0 | -722,066 | -100.0% | -$1.0M | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| SANGAMO THERAPEUTICS, INC | OTC: SGMOQ | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,294,652 | -100.0% | -$0.9M | Q4 2025 | 18 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: ACRS | Exited | Pharmaceutical Preparations | COM | 0 | -350,000 | -100.0% | -$0.9M | $555M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| First Tracks Biotherapeutics, Inc. | Nasdaq: TRAX | Exited | Pharmaceutical Preparations | ORD SHS | 0 | -42,775 | -100.0% | -$0.9M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| VERU INC. | Nasdaq: VERU | Exited | Pharmaceutical Preparations | COM | 0 | -1,425,239 | -100.0% | -$0.8M | $36M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Direxion Shares Etf Trust | Exited | Fund | DAI BIO BEA ETF | 0 | -105,822 | -100.0% | -$0.8M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q2 2026 | 13F, Q2 2026 | |||||
| Iteos Therapeutics Inc | Exited | COM | 0 | -78,574 | -100.0% | -$0.8M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Kezar Life Sciences Inc | Exited | COM NEW | 0 | -102,211 | -100.0% | -$0.8M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Tvardi Therapeutics, Inc. | Nasdaq: TVRD | Exited | Pharmaceutical Preparations | COM | -100.0% | -$0.7M | Q4 2025 | 18 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Mind Medicine Mindmed Inc | Exited | COM NEW | 0 | -62,691 | -100.0% | -$0.7M | Q4 2025 | 18 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| 89bio Inc | Exited | COM | 0 | -100,000 | -100.0% | -$0.7M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||
| Centessa Pharmaceuticals PLC | Exited | SPONSORED ADS | 0 | -18,113 | -100.0% | -$0.7M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Kalvista Pharmaceuticals Inc | Exited | COM | 0 | -35,119 | -100.0% | -$0.7M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: INSM | Exited | Pharmaceutical Preparations | COM PAR $.01 | 0 | -4,214 | -100.0% | -$0.7M | $31.7B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: GLUE | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -136,575 | -100.0% | -$0.6M | $761M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Prothena Corp PLC | Exited | SHS | -100.0% | -$0.6M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||||
| Inhibrx Biosciences, Inc. | Nasdaq: INBX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -42,122 | -100.0% | -$0.6M | $1.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Pyxis Oncology, Inc. | Nasdaq: PYXS | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -613,253 | -100.0% | -$0.6M | $201M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Springworks Therapeutics Inc | Exited | COM | 0 | -12,519 | -100.0% | -$0.6M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Yarrow Bioscience, Inc. | Nasdaq: YARW | Exited | Pharmaceutical Preparations | COM | 0 | -290,000 | -100.0% | -$0.5M | $217M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | |||
| Elevation Oncology Inc | Exited | COM | 0 | -690,089 | -100.0% | -$0.4M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Biomx Inc | Exited | COM NEW | 0 | -892,976 | -100.0% | -$0.4M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Vigil Neuroscience Inc | Exited | COM | 0 | -31,360 | -100.0% | -$0.2M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Anebulo Pharmaceuticals, Inc. | OTC: ANEB | Exited | Pharmaceutical Preparations | COM | 0 | -157,720 | -100.0% | -$0.2M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Lyra Therapeutics Inc | LYRA | Exited | COM NEW | 0 | -21,161 | -100.0% | -$0.2M | $0.1M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Aethlon Med Inc | Exited | COM NEW | 0 | -153,659 | -100.0% | -$0.2M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 |